UK markets close in 5 hours 39 minutes
  • FTSE 100

    7,539.65
    -18.84 (-0.25%)
     
  • FTSE 250

    19,486.19
    +76.77 (+0.40%)
     
  • AIM

    854.09
    +3.53 (+0.42%)
     
  • GBP/EUR

    1.1648
    +0.0005 (+0.04%)
     
  • GBP/USD

    1.2260
    +0.0004 (+0.03%)
     
  • BTC-GBP

    13,834.32
    -180.12 (-1.29%)
     
  • CMC Crypto 200

    402.22
    -3.93 (-0.97%)
     
  • S&P 500

    4,076.57
    -3.54 (-0.09%)
     
  • DOW

    34,395.01
    -194.76 (-0.56%)
     
  • CRUDE OIL

    81.19
    -0.03 (-0.04%)
     
  • GOLD FUTURES

    1,815.00
    -0.20 (-0.01%)
     
  • NIKKEI 225

    27,777.90
    -448.18 (-1.59%)
     
  • HANG SENG

    18,675.35
    -61.09 (-0.33%)
     
  • DAX

    14,511.42
    +21.12 (+0.15%)
     
  • CAC 40

    6,741.48
    -12.49 (-0.18%)
     

Abivax releases the results of its November 9, 2022 ad hoc ordinary and extraordinary general meeting

EQS-News: ABIVAX / Key word(s): AGM/EGM
Abivax releases the results of its November 9, 2022 ad hoc ordinary and extraordinary general meeting
15.11.2022 / 18:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

ABIVAX RELEASES THE RESULTS OF ITS NOVEMBER 9, 2022 AD HOC ORDINARY AND EXTRAORDINARY GENERAL MEETING

  • Shareholders approved all proposed resolutions

PARIS, France, November 15, 2022 – 6:00 p.m. (CET) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, held an ad hoc ordinary and extraordinary general meeting of shareholders on November 9, 2022, which was chaired by Prof. Hartmut Ehrlich, M.D., CEO of Abivax, in the absence of the Chairman of the Board of Directors.

The shareholders have adopted all the resolutions approved by the Board of Directors and, in particular, delegations granted to the Board of Directors related to financial transactions and incentive mechanisms for the benefit of the Company’s employees, managers and/or other partners.

Details on the vote results will be available on the company’s website.

*****

About Abivax (www.abivax.com)

Abivax, a phase 3 clinical stage biotechnology company, is developing novel therapies that modulate the body’s natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, obefazimod (ABX464) to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

Contacts

Abivax                 
Communications
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63

Investors
LifeSci Advisors
Ligia Vela-Reid
lvela-reid@lifesciadvisors.com
+44 7413 825310

Press Relations & Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22

Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24

Public Relations France
Primatice
Thomas Roborel de Climens
thomasdeclimens@primatice.com
+33 6 78 12 97 95

Public Relations USA     
Rooney Partners LLC
Jeanene Timberlake
jtimberlake@rooneypartners.com
+1 646 770 8858


15.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

show this
show this